Some good news for those on NOAC. New drug - Clinical trials were stopped early because of good outcomes. Not sure when it will be ready for patients.
[
www.acc.org]
Press Release: Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation.